The use of mandibular advancement devices in adult patients affected by obstructive sleep apnea syndrome: our experience with Thornton Adjustable Positioner® splint.
| Autor: | Cavarra F; Sant'Andrea Hospital, Vercelli, Italy., Boffano P; Maggiore della Carità Hospital, Novara, Italy - paolo.boffano@gmail.com., Tricarico G; Sant'Andrea Hospital, Vercelli, Italy., Tepedino M; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Brucoli M; Maggiore della Carità Hospital, Novara, Italy.; University of Eastern Piedmont, Novara, Italy., Rocchetti V; Sant'Andrea Hospital, Vercelli, Italy.; University of Eastern Piedmont, Novara, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Minerva dental and oral science [Minerva Dent Oral Sci] 2022 Jun; Vol. 71 (3), pp. 163-167. Date of Electronic Publication: 2021 Apr 30. |
| DOI: | 10.23736/S2724-6329.21.04458-2 |
| Abstrakt: | Background: Obstructive sleep apnea syndrome (OSAS) is a sleep-related disorder resulting in apneic and hypopneic episodes during sleep. The purpose of this article was to present and discuss our experience with the Thornton Adjustable Positioner ® (TAP) Splint (Scheu-Dental GmbH, Iserlohn, Germany; Orthosystem, Milan, Italy) in a consecutive series of patients affected by OSAS. Methods: The data of all patients affected by OSAS and with indication to oral appliance (OA) treatment at the Department of Dentistry of the Hospital of Vercelli between January 1, 2019, and December 31, 2019, were collected. The following data were recorded for each patient: gender, age, smoke and/or alcohol assumption, BMI, comorbidities and current pharmacological therapy, initial AHI, OSAS category, eventual performed OSAS treatment options before OA treatment, indication to OA treatment, final AHI following OA treatment, complications and side effects. Results: A total of 18 subjects (11 men, 7 women) with a mean age of 58.8 years were enrolled in this study with a mean AHI of 27.9 (range 5.884). Average BMI was 29. OA treatment reduced AHI in all patients (mean post treatment AHI: 5; range: 3.1-8). All patients were satisfied with the subjective improvement of OSAS symptoms. Conclusions: Our results confirm the usefulness of a specific type of mandibular advancement device that can be considered as a valuable therapeutic modality in OSAS patients. Side effects are limited, and they usually do not decrease the compliance of patients. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|